Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Status:
Terminated
Trial end date:
2020-12-02
Target enrollment:
Participant gender:
Summary
The FIL_VERT study is a phase II, open label, multicenter clinical trial. The primary of
objective of the Study is to evaluate the efficacy of Venetoclax ABT-199/GDC-0199) in terms
of overall response rate (ORR) in patients with relapsed/refractory BCL-2 positive peripheral
T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL)
and other nodal T-cell lymphomas of T-follicular helper origin (TFH)